Roivant Sciences Ltd.

ROIV Nasdaq CIK: 0001635088

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation Bermuda
Country United Kingdom
Business Address 7TH FLOOR, 50 BROADWAY, LONDON, , SW1H 0DB
Mailing Address 7TH FLOOR, 50 BROADWAY, LONDON, , SW1H 0DB
Phone 441-295-5950
Fiscal Year End 0331
EIN 981173944

Financial Overview

FY2024

$4.35B
Net Income
$7.22B
Total Assets
$773.95M
Total Liabilities
$5.97B
Stockholders' Equity
$6.49B
Cash & Equivalents
$5.55
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 30, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
8-K/A Current report amendment March 23, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 6, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC

Material Events

8-K Legal Issue March 3, 2026
High Impact
  • Secured $950 million guaranteed payment from Moderna patent settlement.
  • Potential for an additional $1.3 billion from ongoing legal appeal.
View Analysis

Insider Trading

STRONG SELL 11 insiders 53 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.